Health outcomes & conditions
GLP-1s for Cardiovascular & Comorbidity Outcomes
GLP-1 medications were developed for diabetes and weight loss, but the most consequential clinical evidence of the last three years has been about what these drugs do for the rest of the body — heart attacks, heart failure with preserved ejection fraction, chronic kidney disease, and obstructive sleep apnea. This cluster collects the research on cardiovascular, kidney, liver, sleep-apnea, and blood-sugar outcomes — anchored in published trials, FDA labels, and peer-reviewed studies.
55 research articles · newest update November 2026
Start with SELECT Trial: Semaglutide Cuts Heart Attack Risk 20%. In the SELECT trial, semaglutide 2.4 mg cut major cardiovascular events by 20% (HR 0.80) in 17,604 adults with obesity and established heart disease but no diabetes. The longest read here, at 16 minutes, is Jardiance, Farxiga, and SGLT2 Inhibitors vs GLP-1s: Weight, Cardio-Renal Benefits, and Where Each Fits in 2026.
Within Health outcomes & conditions, the neighboring topic is GLP-1s, Sexual Health, Fertility & Hormones (79 articles). After that comes GLP-1s, Mental Health, Cravings & the Brain (41 articles). The full map is on all research topics.
Start here
SELECT Trial: Semaglutide Cuts Heart Attack Risk 20%
In the SELECT trial, semaglutide 2.4 mg cut major cardiovascular events by 20% (HR 0.80) in 17,604 adults with obesity and established heart disease but no diabetes. The benefit appeared largely independent of weight loss. What the trial measured and what it changes.
13 min read · Updated November 2026
STEP-HFpEF: How Semaglutide Treats Heart Failure With Preserved Ejection Fraction
In STEP-HFpEF, semaglutide 2.4 mg improved heart failure symptoms and function in adults with HFpEF and obesity, with a 7.8-point KCCQ-CSS gain over placebo at 52 weeks. The pooled analysis covered 1,145 patients. This article places it alongside SGLT2 inhibitors.
14 min read · Updated November 2026
FLOW: How Semaglutide Became the First GLP-1 Approved for Diabetic Kidney Disease
In the FLOW trial of 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide 1.0 mg cut major kidney and cardiovascular events by 24% and was stopped early for benefit. The FDA approved Ozempic for kidney protection on January 28, 2025, a first for a GLP-1.
13 min read · Updated August 2026
Tirzepatide for Sleep Apnea: What SURMOUNT-OSA Showed and the FDA's First-Ever OSA Drug Approval
In SURMOUNT-OSA, tirzepatide cut the apnea-hypopnea index by 25 to 29 events per hour, with and without CPAP, in adults with moderate-to-severe sleep apnea and obesity. The trial led to Zepbound becoming the first FDA-approved drug for obstructive sleep apnea.
11 min read · Updated August 2026
Does a GLP-1 Affect Blood Pressure? Lower, Higher, or Both — The Evidence
GLP-1s lower systolic blood pressure by about 5-7 mmHg on average, through weight loss and direct vascular effects; a small subset sees dose-dependent heart-rate increases. Evidence from STEP-1, SURMOUNT-1, SELECT and drug interactions.
11 min read · Updated November 2026
GLP-1s and Pregnancy, PCOS, and Fertility: What the FDA Labels and the Trial Evidence Actually Say
No GLP-1 label lists pregnancy as a contraindication, but all warn of fetal harm, and weight-loss labels say to stop once pregnancy is recognized. Only Wegovy and Ozempic name a 2-month pre-conception window. PCOS trials, the contraception interaction, and fertility.
13 min read · Updated November 2026
All 55 articles in this topic
Most recently updated first, after the editor’s picks.
- SELECT Trial: Semaglutide Cuts Heart Attack Risk 20%13 min · November 2026
- STEP-HFpEF: How Semaglutide Treats Heart Failure With Preserved Ejection Fraction14 min · November 2026
- FLOW: How Semaglutide Became the First GLP-1 Approved for Diabetic Kidney Disease13 min · August 2026
- Tirzepatide for Sleep Apnea: What SURMOUNT-OSA Showed and the FDA's First-Ever OSA Drug Approval11 min · August 2026
- Does a GLP-1 Affect Blood Pressure? Lower, Higher, or Both — The Evidence11 min · November 2026
- GLP-1s and Pregnancy, PCOS, and Fertility: What the FDA Labels and the Trial Evidence Actually Say13 min · November 2026
- Does a GLP-1 Affect Your Period? Menstrual Cycle Changes, Hormones, and the PCOS Connection11 min · November 2026
- Jardiance, Farxiga, and SGLT2 Inhibitors vs GLP-1s: Weight, Cardio-Renal Benefits, and Where Each Fits in 202616 min · November 2026
- Ozempic for Prediabetes: FDA Indications, STEP-1 Data & DPP First-Line Review14 min · July 2026
- Wegovy for MASH, MAFLD & Fatty Liver: FDA Approval & ESSENCE Evidence Review15 min · November 2026
- Ozempic Babies: Fertility, Pregnancy & Contraception on GLP-1 — Evidence Review12 min · July 2026
- Does Semaglutide Lower Inflammation? The hsCRP Evidence8 min
- Semaglutide and Kidneys: Pooled SELECT, FLOW and SOUL Results7 min
- Does Tirzepatide Lower Atrial Fibrillation Risk? What a 2026 Meta-Analysis Found7 min
- SMART Trial: Semaglutide 2.4 mg in Kidney Disease Without Diabetes8 min
- Time-Restricted Eating for Prediabetes: Glucose Effects8 min
- Tirzepatide in Type 1 Diabetes: The Phase 2 Trial Results8 min
- Does Semaglutide Help You Live Longer? Longevity, Mortality and Aging Evidence8 min · November 2026
- ESSENCE: Semaglutide for MASH Fibrosis (2026)13 min · November 2026
- FLOW Trial Update: GLP-1 for CKD Stage 3-4 — The Evidence12 min · November 2026
- FLOW Trial: Semaglutide Kidney Subgroup Detail (2026)13 min · November 2026
- GLP-1 and Atrial Fibrillation: SELECT, FLOW, and Anticoagulation Stack11 min · November 2026
- GLP-1 for Fatty Liver & MASH: The Patient Action Plan13 min · November 2026
- GLP-1 for HFpEF: STEP-HFpEF + SUMMIT Tirzepatide Trial Results12 min · November 2026
- GLP-1 in Dialysis and Stage 5 CKD: What the Evidence Shows11 min · November 2026
- GLP-1 on Dialysis and in ESRD (2026)12 min · November 2026
- GLP-1 Vascular Effects: Beyond Weight on Plaque (2026)12 min · November 2026
- GLP-1 with Kidney Disease (CKD): The Patient Action Plan14 min · November 2026
- GLP-1s for Type 1 Diabetes: The Off-Label Evidence (Ozempic, Wegovy, Mounjaro, Zepbound)12 min · November 2026
- SELECT Trial: Beyond MACE - Secondary Endpoints (2026)13 min · November 2026
- Should You Wear a CGM on a GLP-1? What the Evidence Shows8 min · November 2026
- SURMOUNT-OSA: How Much Does Zepbound Improve Sleep Apnea?12 min · November 2026
- SURPASS-CVOT: Tirzepatide Cardiovascular Outcomes (2026)13 min · November 2026
- Wegovy and Zepbound for HFpEF Heart Failure: The Patient Guide to STEP-HFpEF and SUMMIT11 min · November 2026
- Wegovy for MASH: ESSENCE Trial Results + FDA Approval Pathway12 min · November 2026
- Zepbound for Sleep Apnea (OSA): The Patient Action Plan13 min · November 2026
- Does Tirzepatide Help You Live Longer? Mortality and Longevity Evidence8 min · October 2026
- Do GLP-1 Drugs Like Ozempic and Mounjaro Lower Stroke Risk? The Evidence9 min · October 2026
- Obesity Hypoventilation Syndrome (Pickwickian Syndrome): Diagnosis, CPAP and Weight Loss11 min · October 2026
- Peripheral Artery Disease, Weight and GLP-1s: What the STRIDE Trial Found11 min · October 2026
- Living Kidney Donation and BMI: Can a GLP-1 Help You Qualify?8 min · September 2026
- Coming Off Blood-Pressure Meds on a GLP-18 min · August 2026
- Does Ozempic Damage Your Kidneys? AKI, Dehydration, and the FLOW Renoprotection Story9 min · August 2026
- GLP-1 and ApoB, Non-HDL & Lp(a): Advanced Lipid Markers8 min · August 2026
- GLP-1 and HFrEF Heart Failure: The Evidence (2026)12 min · August 2026
- GLP-1 and Liver Enzymes (ALT, AST, GGT): What Changes8 min · August 2026
- GLP-1 and Triglycerides: How Your Lipids Change7 min · August 2026
- GLP-1 With Cirrhosis & Portal Hypertension: Safe? (2026)12 min · August 2026
- GLP-1, Fasting Insulin & HOMA-IR: Insulin Resistance7 min · August 2026
- Mounjaro and Blood Pressure: Does Tirzepatide Lower It? (2026)8 min · August 2026
- Mounjaro and Your Kidneys: Risks, Benefits & What the Evidence Shows (2026)8 min · August 2026
- Ozempic and Blood Pressure: Does Semaglutide Lower It? (2026)8 min · August 2026
- Ozempic and Your Kidneys: Risks, Benefits & What the Evidence Shows (2026)8 min · August 2026
- The eGFR Dip on a GLP-1: Kidney Damage or Normal?8 min · August 2026
- Zepbound for Sleep Apnea: The First Drug FDA-Approved for OSA (2026)9 min · August 2026